Physician profile
John Saurino
NPI 1245274117
$785.30
in general payments reported to CMS, 2019-2025
13 companies · $75.25 in 2025
The $75.25 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $86.74 · 2021: $103 · 2022: $186 · 2023: $56.02 · 2024: $105 · 2025: $75.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $236.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $153.32 | 2019-2022 | |
| Genentech USA, INC. | $94.18 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $89.19 | 2021-2024 | Eylea |
| Iridex Corporation | $73.91 | 2024 | |
| Coherus Oncology, INC. | $57.61 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $54.07 | 2019-2021 | |
| Astellas Pharma US INC | $48.06 | 2025 | Izervay |
| Bausch & Lomb Americas INC. | $41.34 | 2022-2023 | Xipere |
| Ani Pharmaceuticals, INC. | $27.19 | 2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $24.81 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.71 | 2021 | |
| Allergan, INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Saurino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.